Study results unveiled at ASCO show combining Enhertu with Perjeta can significantly delay tumor growth versus a regimen that ...

London: AstraZeneca Plc and Daiichi Sankyo Co.’s Enhertu delayed the advance of a common type of breast cancer by more than a ...

AstraZeneca PLC on Monday said Enhertu reduced the risk of disease progression in a form of breast cancer. The Cambridge, England-based pharmaceutical company said Enhertu plus pertuzumab reduced the ...

Three new cancer drugs could help AstraZeneca make a dent in its lofty ambition to become an $80 billion company by 2030.

AstraZeneca and Daiichi Sankyo’s Enhertu plus Roche’s Perjeta demonstrated the potential to shake up first-line treatment of ...

AstraZeneca and Daiichi Sankyo’s drug extended survival by 30% compared to a widely used regimen, further establishing its ...

As such, "the combination of T-DXd and pertuzumab may represent a new first-line standard of care for patients with ...

Improvements in OS and PFS with ENHERTU were consistent across subgroups. “Gastric cancer is particularly challenging to treat, especially in the advanced stages where the five-year survival ...

Researchers at ASCO's annual meeting also discussed the importance of repeat biopsies to assess HER2 status after first-line treatment.

AstraZeneca/Daiichi's Enhertu shows survival benefit vs standard care in HER2+ gastric cancer patients, with 14.7 vs 11.4 ...

The BREAKWATER study enrolled patients with newly diagnosed colon cancer that harbors a mutation called BRAF 600E that makes ...

The safety profile of ENHERTU in DESTINY-Gastric04 was consistent with previous gastric cancer clinical trials with no new safety concerns identified. ENHERTU is currently approved in more than 70 ...